JERUSALEM, March 3, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)
(http://www.oramed.com), a clinical-stage pharmaceutical company
focused on the development of oral drug delivery systems, announced
today that it will be presenting detailed results from its recently
completed Phase 2a FDA trial on ORMD-0801, its orally ingestible
insulin capsule at the 2014 GTC Diabetes Summit taking place from
April 23-25, 2014, in Boston, Massachusetts, USA.
Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will be presenting the data
during the New Therapeutic Targets for Diabetes session.
This was a randomized, double-blind, placebo-controlled Phase 2a
study designed to assess the safety and tolerability of multiple
bedtime doses of the ORMD-0801 oral insulin formulation in adult
Type 2 diabetes patients inadequately controlled with diet alone or
diet and metformin. Preliminary results were announced by the
company on January 30th of
this year.
Presentation Details
Title: The Tolerability and Efficacy of Oral Insulin in Type 2
Diabetes Patients: A Pilot Clinical Study
Time: 3:15 on April
24th 2014
Location: Hyatt Regency Cambridge, MA
The presentation slides will be available on the Company's
website simultaneous with the Diabetes Summit.
About ORMD-0801 Oral Insulin
Oramed's ORMD-0801 is an orally ingestible insulin capsule for
the early stages of type 2 diabetes, when it can still slow the
rate of degeneration of the disease by providing additional insulin
to the body and allowing pancreatic respite. Moreover, orally
administered insulin has the potential benefit of enhanced patient
compliance at this crucial stage as well as the advantage of
mimicking insulin's natural location and gradients in the body by
first passing through the liver before entering the bloodstream.
For more information on ORMD-0801, please visit:
http://oramed.com.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs and vaccines currently delivered
via injection. Established in 2006, Oramed's Protein Oral Delivery
(POD[TM]) technology is based on
over 30 years of research by top research scientists
at Jerusalem's Hadassah Medical Center. Oramed is seeking
to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently in Phase 2 clinical trials on patients with type 2
diabetes (T2DM) under an Investigational New Drug application with
the U.S. Food and Drug Administration, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog). Oramed is also moving forward
with clinical trials of ORMD-0801 for the treatment of type 1
diabetes. The company's corporate and R&D headquarters are
based in Jerusalem.
For more information, the content of which is not part of
this press release, please
visit http://www.oramed.com
Forward-looking statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, we are using
forward-looking statements when we discuss our clinical trials,
including the expected timing, the anticipated safety of ORMD-0801
and revolutionizing the treatment of diabetes with our products.
These forward-looking statements are based on the current
expectations of the management of Oramed only, and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact:
Oramed Pharmaceuticals
Aviva Sherman-Guiloff
Office: +972-2-566-0001
US: +1-718-831-2512
Email: aviva@oramed.com
SOURCE Oramed Pharmaceuticals Inc.